{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:59:51Z","timestamp":1781020791998,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102121","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:20:08Z","timestamp":1771658408000},"page":"102121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treosulfan\u2013based conditioning regimen for allogeneic HSCT in children with AML: study of the Polish Pediatric Study Group for HSCT"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-6646","authenticated-orcid":false,"given":"Agnieszka","family":"Sobkowiak-Sobierajska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Zaj\u0105c-Spycha\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2745-120X","authenticated-orcid":false,"given":"Monika","family":"Mielcarek-Siedziuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Ka\u0142wak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-7996","authenticated-orcid":false,"given":"Agnieszka","family":"Zaucha-Pra\u017cmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-9129","authenticated-orcid":false,"given":"Katarzyna","family":"Drabko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"D\u0119bski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Styczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Go\u017adzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102121_bib0001","series-title":"The EBMT Handbook \u2013 hematopoietic stem cell transplantation and cellular therapies","first-page":"633","article-title":"Acute myeloid leukaemia in children","author":"Gibson","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102121_bib0002","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102121_bib0003","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2021005224","article-title":"Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen","volume":"6","author":"Versluijs","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl. 1","key":"10.1016\/j.jcyt.2026.102121_bib0004","article-title":"Intravenous treosulfan in conditioning before allogeneic HSCT from MSD in children with high risk of toxic complications related to conventional preparative regimen","volume":"30","author":"Wachowiak","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0005","first-page":"S190","article-title":"Differential toxicity profile of busulfan and treosulfan on endothelial cells in vivo - relevance to hematopoietic stem cell transplantation","volume":"25","author":"Balakrishnan","year":"2019"},{"key":"10.1016\/j.jcyt.2026.102121_bib0006","doi-asserted-by":"crossref","first-page":"529.e1","DOI":"10.1016\/j.jtct.2023.05.003","article-title":"Effect of busulfan and treosulfan on gonadal function after allogeneic stem cell transplantation in children and adolescents with nonmalignant diseases is not exposure-dependent","volume":"29","author":"van der Stoep","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102121_bib0007","doi-asserted-by":"crossref","first-page":"99.e1","DOI":"10.1016\/j.jtct.2021.09.018","article-title":"Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: a prospective multicenter study","volume":"28","author":"van der Stoep","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102121_bib0008","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/bmt.2010.343","article-title":"Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party","volume":"46","author":"Wachowiak","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0009","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s ? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"10.1016\/j.jcyt.2026.102121_bib0010","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1038\/bmt.2008.53","article-title":"Early complications following haematopoietic SCT in children","volume":"41","author":"Miano","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0011","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41409-020-0806-8","volume":"55","author":"Saglio","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0012","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102121_bib0013","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00277-014-2196-8","article-title":"Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia","volume":"94","author":"Boztug","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102121_bib0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bmt.1703337","article-title":"Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia","volume":"29","author":"Balduzzi","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0015","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.bbmt.2012.05.006","article-title":"Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution","volume":"18","author":"Law","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0016","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bbmt.2008.06.009","article-title":"Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide","volume":"14","author":"Bredeson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102121_bib0018","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0019","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0020","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.bbmt.2013.09.012","article-title":"Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia","volume":"19","author":"Kato","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0021","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.bbmt.2015.08.011","volume":"21","author":"Ishida","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0022","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbmt.2016.11.022","volume":"23","author":"Lucchini","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0023","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102121_bib0024","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41409-020-0869-6","article-title":"Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies","volume":"55","author":"Kalwak","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102121_bib0026","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.bbmt.2007.07.002","article-title":"Second malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Lowe","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11864-018-0528-y","article-title":"Second malignancies after hematopoietic stem cell transplantation","volume":"19","author":"Danylesko","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jcyt.2026.102121_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.731478","article-title":"Treosulfan-based conditioning regimen prior to allogeneic stem cell transplantation: long-term results from a phase 2 clinical trial","volume":"11","author":"Lazzari","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102121_bib0029","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pbc.25764","article-title":"European society for blood and marrow transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies","volume":"63","author":"Boztug","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jcyt.2026.102121_bib0030","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.exphem.2010.08.006","article-title":"Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia","volume":"38","author":"Wiedemann","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2026.102121_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720949175","article-title":"Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil: a multicentric retrospective study","volume":"29","author":"de Melo Rodrigues","year":"2020","journal-title":"Cell Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102121_bib0032","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","article-title":"Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial","volume":"59","author":"Sykora","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102121_bib0033","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcyt.2026.102121_bib0034","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.16594","article-title":"Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting","volume":"190","author":"Hanekamp","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jcyt.2026.102121_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102121_bib0036","first-page":"701","article-title":"Maximal benefit of minimal residual disease monitoring in pediatric acute myeloid leukemia","volume":"109","author":"Hasle","year":"2024","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:20:49Z","timestamp":1781018449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926000836"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102121","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treosulfan\u2013based conditioning regimen for allogeneic HSCT in children with AML: study of the Polish Pediatric Study Group for HSCT","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102121"}}